.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median consequence of 11 months, patients with metastatic intestinal growths who received biomarker-matched therapies based upon circulating growth DNA profiling revealed a greater clinical benefit than those obtaining unparalleled treatment.